Skip to main content

Table 3 Three and 5-year data in patients receiving 48 Gy/4 Fr, 50 Gy/4 Fr, and 52 Gy/4 Fr

From: Stereotactic body radiotherapy for stage I non-small-cell lung cancer using higher doses for larger tumors: results of the second study

 

48 Gy/4 Fr (n = 6)

50 Gy/4 Fr (n = 51)

52 Gy/4 Fr (n = 14)

OS (%) at 3/5 years

100/100

70/65

71/53

PFS (%) at 3/5 years

83/63

62/55

64/54

Cumulative incidence of LR (%) at 3/5 years

0/20

10/10

22/31

  1. OS Overall survival, PFS Progression free survival, LR Local recurrence